Pfizer Inc has released data from its maternal respiratory syncytial virus (RSV) vaccine candidate which suggest strong efficacy, and could see it take a bigger than expected slice of a soon-to-be multi-billion dollar market.
An abstract from a Phase IIb study being presented at the RSV Vaccines for the World Conference (RSVVW) conference (being...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?